Analysts think BMY stock price could increase by 17%
Jun 04, 2025, 11:25 AM
-2.44%
What does BMY do
Bristol Myers Squibb Co., based in Princeton, NJ, employs 34,100 staff and develops biopharmaceuticals across various therapeutic classes, including oncology and immunology. Key products include Eliquis and Opdivo, with a strong pipeline featuring Krazati and KarXT.
24 analysts think BMY stock price will increase by 16.62%. The current median analyst target is $56.10 compared to a current stock price of $48.10. The lowest analysts target is $33.43 and the highest analyst target is $71.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
